国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于苏交科集团股份有限公司 2024 年度股东大会的法律意见书 致：苏交科集团股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受苏交科集团股份有限公 司（以下简称"公司"）的委托，指派本所律师出席公司 2024 年度股东大会（以 下简称"本次股东大会"）。本所律师依据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东大会规则》 （以下简称"《股东大会规则》"）等法律、法规、规章和《苏交科集团股份有 限公司章程》（以下简称"《公司章程》"）的规定，就公司本次股东大会的召 集与召开程序、出席会议人员资格、召集人资格、会议表决程序和表决结果的合 法性等有关法律问题出具法律意见书。 本法律意见书依据国家有关法律、法规的规定而出具。本所律师同意将本法 律意见书随公司本次股东大会决议一起公告，并依法对本法律意见书承担相应的 责任。本法律意见书不存在虚假、严重误导性陈述及重大遗漏。 本法律意见书仅供公司 2024 年度股东大会见证之目的 ...

Group 1 - Shengxiang Bio plans to increase its investment in Hunan Shengwei Kunteng Biotechnology Co., Ltd. by 100 million yuan to enhance its industrial chain layout in the POCT field, resulting in a 44.6441% stake in Shengwei Kunteng after the investment [1] - Yaguang Technology's subsidiary Chengdu Yaguang signed a product pre-production agreement worth 101 million yuan, accounting for 10.56% of the company's audited revenue for the last fiscal year [1] Group 2 - Chutianlong's shareholder plans to reduce its stake by up to 3%, equating to 13.83 million shares, due to personal funding needs [2] - Naipu Mining intends to invest up to 45 million USD in Swiss Veritas Resources AG, acquiring a 22.5% stake to extend its industrial chain [2][3] Group 3 - Diri Medical's shareholder plans to reduce its stake by up to 3%, totaling 814.83 thousand shares, due to funding needs [4] - Kangtai Medical's controlling shareholder plans to reduce its stake by up to 2.99%, equating to 12 million shares [5] Group 4 - Iwu Bio's controlling shareholder plans to transfer up to 450 thousand shares through block trading, representing 0.86% of the total share capital [7] - Guokai Hengtai's four shareholders plan to collectively reduce their stake by up to 4.7%, totaling 22.94 million shares [9] Group 5 - *ST Zhongcheng submitted a hearing application to the Shenzhen Stock Exchange in response to a delisting notice [10] - Donghua Software's actual controller and associated parties plan to reduce their stake by up to 1%, totaling 32.05 million shares [12] Group 6 - Shandong Molong's shareholder reduced its H-share holdings by 107 million shares, representing 13.39% of the total share capital [12] - Yinbang Co.'s shareholder plans to reduce its stake by up to 1%, totaling 821.92 thousand shares [13] Group 7 - Jinxinnong reported April sales of 10.65 million pigs, generating sales revenue of 139 million yuan, with an average selling price of 15.05 yuan per kilogram [14] - Dongfang Jiasheng purchased 9.54 million shares of Zhonggu Logistics for approximately 99.72 million yuan, representing 4.18% of the company's net assets [15] Group 8 - Linglong Tire's controlling shareholder received a financing commitment of up to 270 million yuan for stock repurchase [16] - Wuchan Jinlun's shareholder plans to reduce its stake by up to 3%, totaling 619.77 thousand shares [18] Group 9 - Pengyao Environmental's directors and executives plan to collectively reduce their stake by up to 0.07% [19] - Ruihu Mould's controlling shareholder plans to reduce its stake by up to 1.92%, totaling 401.89 thousand shares [20] Group 10 - Electric Alloy's shareholder plans to reduce its stake by up to 0.63%, totaling 210.88 thousand shares [22] - Shanghai Xinyang's controlling shareholder plans to reduce its stake by up to 0.64%, totaling 200 thousand shares [24] Group 11 - Sujiao Ke's controlling shareholder plans to acquire up to 2% of the company's shares from a fund [26] - Heyuan Bio's shareholders plan to reduce their stake by up to 1%, totaling 649.04 thousand shares [27]

特别提示： 证券代码：300284 证券简称：苏交科 公告编号：2025-031 苏交科集团股份有限公司 关于控股股东拟受让广州国资产业发展并购基金合伙企业（有 限合伙）股份计划的提示性公告 公司股东广州珠江实业集团有限公司与广州国资产业发展并购基金合伙企 业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1、截至本公告披露日，苏交科集团股份有限公司（以下简称"公司"）控股 股东广州珠江实业集团有限公司（以下简称"珠实集团"）持有公司股份 291,421,794 股，占公司总股本的 23.0769%；公司股东广州国资产业发展并购基 金合伙企业（有限合伙）（以下简称"国发基金"）持有公司股份 48,570,299 股， 占公司总股本的 3.8462%。珠实集团与国发基金的一致行动关系至 2024 年 12 月 31 日终止，根据《深圳证券交易所上市公司自律监管指引第 18 号——股东 及董事、监事、高级管理人员减持股份》，公司控股股东及其一致行动人之间解 除一致行动关系的，相关方还应当在六个月内继 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4]. Core Insights - The company experienced a revenue decline of 10.40% year-on-year in 2024, with total revenue reaching 4.73 billion yuan and a net profit attributable to shareholders of 224 million yuan, down 31.92% year-on-year. The first quarter of 2025 also saw a revenue decrease of 9.00% year-on-year [1][6]. - Despite the challenges in traditional infrastructure investment and increased competition in the engineering consulting industry, the company maintains a stable industry position, ranking 67th and 85th in the global engineering design company lists by ENR [1]. - The company is focusing on transforming its business structure and accelerating its entry into the low-altitude economy, having established a research institute for low-altitude economic development in Jiangsu Province [2]. Financial Performance - The company's gross margin for 2024 was 34.76%, a decrease of 1.23 percentage points year-on-year. The net profit margin was 4.97%, down 0.84 percentage points year-on-year [3]. - For the first quarter of 2025, the gross margin was reported at 29.07%, with a net profit margin of 4.53%, attributed to intensified industry competition and increased financial costs [3]. Earnings Forecast - The company is expected to see earnings per share (EPS) of 0.19, 0.21, and 0.23 yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (P/E) ratios of 45, 41, and 37 [4][6].

Core Viewpoint - The company reported a decline in revenue and net profit for Q1 2025, but is focusing on digitalization and low-altitude economy as new growth areas, maintaining a "buy" rating [1][5]. Financial Performance - Q1 2025 revenue was 809 million yuan, down 9.0% year-on-year, with a net profit attributable to shareholders of 43.11 million yuan, down 19.1% year-on-year [1]. - The comprehensive gross profit margin for Q1 2025 was 29.1%, an increase of 3.84 percentage points year-on-year, while the net profit margin was 5.3%, a decrease of 0.66 percentage points year-on-year [2]. - Operating cash flow outflow decreased, with a cash collection ratio of 118.2%, up 2.3 percentage points year-on-year, indicating improved cash flow [2]. Cost and Expenses - The total expense ratio for Q1 2025 was 22.5%, an increase of 4.37 percentage points year-on-year, with financial expenses rising to 17.59 million yuan due to increased exchange losses [1][2]. - Impairment expenses accounted for 0.5% of revenue, up 0.44 percentage points year-on-year [1]. Strategic Initiatives - The company is actively investing in digitalization and low-altitude economy sectors, having implemented over 70 demonstration projects in bridge monitoring and emergency response [4]. - It has participated in over 60 major aviation consulting projects and established a research institute for low-altitude economic development [4]. Earnings Forecast and Valuation - The company maintains its EPS forecast for 2025-2027 at 0.20, 0.22, and 0.23 yuan respectively, with a target price of 10.48 yuan based on a PE ratio of 53 times for 2025 [5].

证券代码：300284 证券简称：苏交科 公告编号：2025-030 苏交科集团股份有限公司 关于使用部分闲置自有资金进行投资理财的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏，并依法对其内容的真实性、准确性和完整性承担 相应责任。 重要内容提示： 1.投资种类：本次拟购买的理财种类为银行结构性存款。 2.投资金额：本次拟使用的资金为 10,000 万元。截止本公告日，公司已购买尚 未赎回的理财产品投资总额为 10,000 万元（含本次购买的 10,000 万元），未超过 2024 年第二次临时股东大会授予的 120,000 万元理财总额度。 3.特别风险提示：公司将根据经济形势以及金融市场的变化适时适量地介入， 短期投资的实际收益不可预期。敬请广大投资者注意投资风险。 苏交科集团股份有限公司（以下简称"公司"）于 2024 年 10 月 26 日召开第 五届董事会第二十次会议及第五届监事会第十七次会议，并于 2024 年 11 月 15 日 召开公司 2024 年第二次临时股东大会，审议通过了《关于继续使用闲置自有资金 进行投资理财的议案》，同意公 ...

Financial Performance - In 2024, the company achieved operating revenue of CNY 4.729 billion, a decrease of 10.40% compared to the previous year [7] - The net profit attributable to shareholders was CNY 224 million, down 31.92% year-on-year [7] - Operating cash flow was CNY 261 million, a decline of 14.91% from the previous year [7] Business Strategy and Market Position - The company is focusing on market expansion and business structure optimization to enhance contract value, targeting areas like "new infrastructure," "dual carbon," and "low-altitude economy" [2][3] - A comprehensive receivables management system has been established to mitigate risks and improve cash flow [3][8] - The company has developed a "value management system" and "negative public opinion management regulations" to enhance market value and manage public perception [3] Industry Outlook - The engineering consulting and contracting industry faces both opportunities and challenges, with government policies supporting sectors like smart transportation and green projects [3] - The company anticipates stable demand in the transportation infrastructure sector, with annual fixed asset investment expected to remain above CNY 3-3.5 trillion [3] Growth Drivers - Technological innovation is a key growth driver, with the establishment of national-level research platforms and numerous patents granted [4][10] - Digital transformation initiatives are underway, focusing on smart upgrades and the development of low-altitude economy services [4][5] - International expansion through subsidiaries, particularly in regions along the Belt and Road Initiative, is a strategic focus [5] Low-altitude Economy Development - The company has established a joint venture for low-altitude flight services and is actively developing a low-altitude flight supervision platform [5][6] - Ongoing projects include the establishment of a low-altitude economic development research institute and collaboration with government bodies for regulatory frameworks [8] Financial Management - The company's accounts receivable as of Q1 2025 accounted for 2046.01% of the latest annual net profit, indicating a significant impact on cash flow [8] - Measures to enhance receivables recovery include risk identification, contract compliance monitoring, and a structured collection mechanism [8] Investment Plans - In 2024, the company increased its investment by 84.22% compared to the previous year, focusing on new business areas and regional expansion [8][9] - Future investments will continue to align with the company's strategic development goals [9]

Investment Rating - The report assigns a neutral investment rating to the company, indicating a performance expectation in line with the market benchmark [12]. Core Views - The company is projected to experience a gradual increase in revenue, with expected figures of 47.29 billion in 2024, 48.60 billion in 2025, 50.70 billion in 2026, and 53.80 billion in 2027, reflecting a compound annual growth rate (CAGR) of approximately 6.11% from 2025 to 2027 [7]. - The net profit attributable to the parent company is forecasted to grow from 2.24 billion in 2024 to 2.97 billion in 2027, indicating a growth rate of 13.40% from 2026 to 2027 [7]. - The company's gross margin is expected to remain stable, with projections of 34.76% in 2024, slightly decreasing to 34.33% by 2027 [7]. - The report highlights a positive trend in cash flow from operating activities, expected to increase significantly from 2.61 billion in 2024 to 8.06 billion in 2027 [6]. Financial Summary - **Income Statement**: - Revenue is projected to grow from 47.29 billion in 2024 to 53.80 billion in 2027, with a corresponding increase in operating profit from 2.87 billion to 3.51 billion [7]. - The net profit is expected to rise from 2.35 billion in 2024 to 3.01 billion in 2027, with a net profit margin increasing from 4.74% to 5.52% [7]. - **Balance Sheet**: - Total assets are forecasted to increase from 160.63 billion in 2024 to 188.01 billion in 2027, with a slight increase in current assets [6]. - The company's total liabilities are expected to remain stable, with a total liability of 72.67 billion in 2024 and 77.09 billion in 2027 [6]. - **Cash Flow Statement**: - Operating cash flow is projected to increase significantly, indicating improved operational efficiency and profitability [6]. - The net cash increase is expected to be negative in 2024 at -1.83 billion but will turn positive in subsequent years, reaching 4.80 billion by 2027 [6]. Key Financial Ratios - The report indicates a projected return on equity (ROE) of 2.67% in 2024, slightly increasing to 2.77% by 2027 [7]. - The price-to-earnings (P/E) ratio is expected to decrease from 49.53 in 2024 to 37.45 in 2027, suggesting a potential increase in valuation attractiveness over time [7]. - The company's debt-to-equity ratio is projected to improve, with a net debt ratio moving from -8.16% in 2024 to -36.69% in 2027, indicating a strong balance sheet position [7].

经与会监事认真审议，本次会议审议通过了以下议案： 一、审议通过了《2025 年第一季度报告》 经审核，监事会认为：董事会编制和审核公司《2025 年第一季度报告》的程序 符合法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了公 司 2025 年第一季度经营的实际情况，不存在任何虚假记载、误导性陈述或重大遗 漏。具体内容详见巨潮资讯网同日披露的《2025 年第一季度报告》。 证券代码：300284 证券简称：苏交科 公告编号：2025-029 苏交科集团股份有限公司 第六届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 苏交科集团股份有限公司（以下简称"公司"）第六届监事会第三次会议通知于 2025 年 4 月 14 日以通讯方式向全体监事发出，会议于 2025 年 4 月 21 日在公司会 议室以现场会议方式召开。本次会议应出席监事 3 人，实际出席监事 3 人。会议由 公司监事会主席刘辉先生主持。本次会议的召开符合《中华人民共和国公司法》等 有关法律、法规和《公司章程》的有关规定。 表决结果：同意 3 票，反对 0 ...

证券代码：300284 证券简称：苏交科 公告编号：2025-028 苏交科集团股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 苏交科集团股份有限公司（以下简称"公司"）第六届董事会第四次会议通知 于 2025 年 4 月 14 日以通讯方式向全体董事发出，会议于 2025 年 4 月 21 日在公 司会议室以现场会议方式召开。本次会议应出席董事 9 人，实际出席董事 9 人。会 议由公司董事长李大鹏先生主持，公司全体监事及部分高级管理人员列席了会议， 本次会议的召开符合《中华人民共和国公司法》等有关法律、法规和《公司章程》 的有关规定。 经与会董事认真审议，本次会议审议通过了以下议案： 一、审议通过了《2025 年第一季度报告》 董事会认为：公司 2025 年第一季度报告真实、准确、完整地反映了公司 2025 年第一季度的财务状况和经营成果，不存在虚假记载、误导性陈述或重大遗漏。具 体内容详见巨潮资讯网同日披露的《2025 年第一季度报告》。 本议案已经公司董事会审计委员会审议通过。 表决结果：同意 9 票，反对 ...